Clinical Trial: TKI 258 in Von Hippel-Lindau Syndrome (VHL)

Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional




Official Title: A Pilot Trial of TKI 258 (Dovitinib) in Von Hippel-Lindau Syndrome

Brief Summary: The goal of this clinical research study is to learn if dovitinib can safely be given to patients who have VHL with a measurable hemangioblastoma (tumor of the central nervous system). The effects of this drug on the disease will also be studied.